Endra Life Sciences Inc Stock Price, News & Analysis

ENDRA Life Sciences (NASDAQ: NDRA) reported Q2 2022 results with a net loss of $3.6 million, or $0.06 per share, compared to a net loss of $3.2 million, or $0.08 per share, in Q2 2021. The company maintained a cash position of approximately $11 million, sufficient to fund operations through key milestones. Notably, ENDRA plans to submit a De Novo request to the FDA in Q3 and has ramped up clinical evaluation, performing over 50 scans. The company also bolstered its IP portfolio with 11 new patents, enhancing commercialization potential.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) will report its second quarter 2022 financial results on August 15, 2022, after market close. A conference call will follow at 4:30 p.m. Eastern time to discuss results and recent developments. Participants can pre-register for immediate access or dial in directly. ENDRA is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, aimed at visualizing tissue efficiently and cost-effectively, focusing initially on liver fat assessment related to NAFLD and NASH.

ENDRA Life Sciences (NASDAQ: NDRA) announces the issuance of three new patents by the U.S. Patent & Trademark Office, expanding its intellectual property portfolio to a total of 53 patents globally, including 31 in the U.S. The newly granted patents focus on methods for exchanging equipment performance data, significantly enhancing ENDRA’s technology for cloud-based data management. This provides potential licensing opportunities with other equipment manufacturers, especially in the medical imaging industry, and strengthens the company's competitive position.

ENDRA Life Sciences (NASDAQ: NDRA) will participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 15-16, 2022. The management team will conduct one-on-one virtual meetings with investors. Interested participants can reach out to Needham or Yvonne Briggs at LHA for meeting requests. ENDRA is known for its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers cost-effective tissue visualization, primarily targeting liver conditions like NAFLD and NASH. This technology integrates with existing ultrasound systems worldwide.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced the issuance of two new patents in China, extending its intellectual property protection for its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology through 2040. The newly granted patents, titled 'Systems and Methods for Thermoacoustic Transducer Optimization' and 'Method and System for Reconstructing a Thermoacoustic Image', enhance ENDRA's patent portfolio to 50 globally. This innovation targets Non-Alcoholic Fatty Liver Disease (NAFLD) and is aimed at the Chinese market, which is home to approximately 350 million affected individuals.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) has announced the issuance of U.S. Patent No. 11369272, which protects its Thermo Acoustic Enhanced UltraSound (TAEUS) technology's radiofrequency (RF) applicator. This patent enhances optimization in RF energy delivery to tissues, minimizing sensitivity to tissue variations. ENDRA's patent portfolio now includes 48 patents globally. The company aims to broaden TAEUS applications in unmet clinical needs. TAEUS is designed for cost-effective imaging, initially targeting liver conditions affecting over one billion people worldwide.

ENDRA Life Sciences (NASDAQ: NDRA), a leader in enhanced ultrasound technology, will present at the JMP Securities Life Sciences Conference in New York City on June 15-16, 2022. The company's overview is scheduled for June 15 at 2:30 PM Eastern time, with additional one-on-one investor meetings available. ENDRA's innovative TAEUS® technology offers MRI-like tissue visualization at 1/50th the cost. Initially targeting Non-Alcoholic Fatty Liver Disease, it has broader applications, including tissue temperature monitoring during surgical procedures.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced the issuance of U.S. Patent No. 11337676, protecting its method for optimizing radiofrequency energy delivery using Thermo Acoustic Enhanced UltraSound (TAEUS®). This patent marks the 27th issued in the U.S. and contributes to ENDRA's strategy of advancing hybrid ultrasound imaging systems. Currently, ENDRA holds 90 IP assets globally and aims to address unmet clinical needs, primarily targeting Non-Alcoholic Fatty Liver Disease (NAFLD) and other applications.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present an overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami Beach. The company focuses on enhanced ultrasound technologies through its innovative TAEUS® system, which aims to visualize tissue akin to MRI at a significantly lower cost. This technology is especially relevant for assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and other liver conditions affecting over one billion individuals globally. The presentation will be available on-demand starting May 24, 2022.